TREATMENT OF APLASTIC ANEMIA WITH ANTI-THYMOCYTE GLOBULIN AND CYCLOSPORIN A

再生障碍性贫血的特征是外周全血细胞减少和 少细胞骨髓。治疗的选择是同种异体骨 来自人类白细胞抗原相合的兄弟姐妹的骨髓移植。不幸的是， 大多数受影响的患者没有资格接受这一手术 因为缺乏合适的捐赠者、高龄或缺乏 财政资源。目前，治疗这些疾病的最好方法是 个体是免疫抑制。在协议90-H-146中，我们正在尝试 通过联合四天的免疫抑制方案优化免疫抑制方案 抗胸腺细胞球蛋白(ATG)和6个月的环孢素A。 共招募了53名患者，正在进行 分析要发布的数据。 患者被允许进入NHLBI血液科临床服务 位于2W。在NHLBI的工作人员中轮流承担出席职责 以及临床中心的工作人员，包括输血医学。 去年没有来自CPD的主治医生，但有三个血液科 高级工作人员计划在来年参加。病人是 由血液学专家照顾。所有数据分析均由Dr。 罗森菲尔德。

Aplastic anemia is characterized by peripheral pancytopenia and a hypocellular bone marrow. The treatment of choice is allogeneic bone marrow transplantation from an HLA-matched sibling. Unfortunately, the majority of affected patients are ineligible for this procedure because of lack of a suitable donor, advanced age, or lack of financial resources. Currently, the best treatment for these individuals is immunosuppression. in protocol 90-H-146 we are trying to optimize the immunosuppressive regimen by combining four days of anti-thymocyte globulin (ATG) and six months of cyclosporine A. We have enrolled a total of 53 patients and are in the process Of analyzing the data for publication. Patients are admitted to the NHLBI Hematology Branch clinical service located on 2W. Attending responsibilities rotate among the NHLBI staff as well as Clinical Center staff, including Transfusion Medicine. There was no attending from CPD last year, but three of the Hematology senior staff are scheduled to attend in the coming year. Patients are cared for by Hematology fellows. All data analysis is performed by Dr. Rosenfeld.